Kotlyar Mischa J, Krebs Markus, Solimando Antonio Giovanni, Marquardt André, Burger Maximilian, Kübler Hubert, Bargou Ralf, Kneitz Susanne, Otto Wolfgang, Breyer Johannes, Vergho Daniel C, Kneitz Burkhard, Kalogirou Charis
Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany.
Cancers (Basel). 2023 Mar 26;15(7):1981. doi: 10.3390/cancers15071981.
(1) Background: Clear cell renal cell carcinoma extending into the inferior vena cava (ccRCC) represents a clinical high-risk setting. However, there is substantial heterogeneity within this patient subgroup regarding survival outcomes. Previously, members of our group developed a microRNA(miR)-based risk classifier-containing miR-21-5p, miR-126-3p and miR-221-3p expression-which significantly predicted the cancer-specific survival (CSS) of ccRCC patients. (2) Methods: Examining a single-center cohort of tumor tissue from = 56 patients with ccRCC, we measured the expression levels of miR-21, miR-126, and miR-221 using qRT-PCR. The prognostic impact of clinicopathological parameters and miR expression were investigated via single-variable and multivariable Cox regression. Referring to the previously established risk classifier, we performed Kaplan-Meier analyses for single miR expression levels and the combined risk classifier. Cut-off values and weights within the risk classifier were taken from the previous study. (3) Results: miR-21 and miR-126 expression were significantly associated with lymphonodal status at the time of surgery, the development of metastasis during follow-up, and cancer-related death. In Kaplan-Meier analyses, miR-21 and miR-126 significantly impacted CSS in our cohort. Moreover, applying the miR-based risk classifier significantly stratified ccRCC according to CSS. (4) Conclusions: In our retrospective analysis, we successfully validated the miR-based risk classifier within an independent ccRCC cohort.
(1) 背景：延伸至下腔静脉的透明细胞肾细胞癌（ccRCC）代表一种临床高危情况。然而，该患者亚组在生存结局方面存在显著异质性。此前，我们团队成员开发了一种基于微小RNA（miR）的风险分类器，包含miR - 21 - 5p、miR - 126 - 3p和miR - 221 - 3p的表达，该分类器能显著预测ccRCC患者的癌症特异性生存（CSS）。(2) 方法：我们检测了来自56例ccRCC患者的肿瘤组织单中心队列，使用qRT - PCR测量miR - 21、miR - 126和miR - 221的表达水平。通过单变量和多变量Cox回归研究临床病理参数和miR表达的预后影响。参照先前建立的风险分类器，我们对单个miR表达水平和联合风险分类器进行了Kaplan - Meier分析。风险分类器中的临界值和权重取自先前的研究。(3) 结果：miR - 21和miR - 126的表达与手术时的淋巴结状态、随访期间转移的发生以及癌症相关死亡显著相关。在Kaplan - Meier分析中，miR - 21和miR - 126对我们队列中的CSS有显著影响。此外，应用基于miR的风险分类器可根据CSS对ccRCC进行显著分层。(4) 结论：在我们的回顾性分析中，我们在一个独立的ccRCC队列中成功验证了基于miR的风险分类器。
